Product Details

CRO market poised for growth and consolidation

CROs have seen strong financial results during the past 18 months, reporting higher revenue and a rebound in profit margins, and they expect another year of healthy growth fueled by strategic partnerships with sponsors and an increase in clinical outsourcing.

Strategies for success evolving in phase I space

Nathan Segall, M.D., had high expectations when he opened his phase I clinical trial unit in Atlanta. So did Chad Jaeger, when his employer, Da Vita Clinical Research, expanded in Denver.

Also in this issue:

• Country and site selection: Best practices
• Navigating mobile regulations in clinical trials
• Regulatory Update
• Month in Review
• FDA Actions
• Study Lead Opportunities
• New Drugs in the Pipeline